Misplaced Pages

Clesrovimab

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Monoclonal antibody
This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (November 2023)
Pharmaceutical compound
Clesrovimab
Monoclonal antibody
Type?
Clinical data
Other namesMK-1654
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
UNII

Clesrovimab (MK-1654) is a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infections. Developed by Merck, it is in a phase III trial as of 2023. It works differently than nirsevimab.

References

  1. Odumade, Oludare A; van Haren, Simon D; Angelidou, Asimenia (15 August 2022). "Implications of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic on the Epidemiology of Pediatric Respiratory Syncytial Virus Infection". Clinical Infectious Diseases. 75 (Supplement_1): S130–S135. doi:10.1093/cid/ciac373. PMC 9129219. PMID 35579506.
  2. Dolgin, Elie (27 September 2023). "Antibody therapies set to transform respiratory syncytial virus prevention for babies". Nature. 621 (7980): S55–S57. doi:10.1038/d41586-023-02957-z. PMID 37758887. S2CID 262894944.
  3. Verwey, Charl; Madhi, Shabir A. (May 2023). "Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus". BioDrugs. 37 (3): 295–309. doi:10.1007/s40259-023-00596-4. PMC 10127166. PMID 37097594.
  4. Cunningham, Steve; Zar, Heather J. (15 June 2023). "New Interventions to Prevent Respiratory Syncytial Virus Disease in Infants—Time for Equitable Global Access". American Journal of Respiratory and Critical Care Medicine. 207 (12): 1556–1557. doi:10.1164/rccm.202303-0568VP. PMC 10273123. PMID 37104655.
  5. Qiu, Xirui; Xu, Siyan; Lu, Yang; Luo, Zichen; Yan, Yangtian; Wang, Chuyue; Ji, Jianjian (December 2022). "Development of mRNA vaccines against respiratory syncytial virus (RSV)". Cytokine & Growth Factor Reviews. 68: 37–53. doi:10.1016/j.cytogfr.2022.10.001. PMID 36280532. S2CID 252877115.
  6. Phuah, Jia Yao; Maas, Brian M.; Tang, Aimin; Zhang, Ying; Caro, Luzelena; Railkar, Radha A.; Swanson, Michael D.; Cao, Yu; Li, Hankun; Roadcap, Brad; Catchpole, Andrew P.; Aliprantis, Antonios O.; Vora, Kalpit A. (December 2023). "Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults". Biomedicine & Pharmacotherapy. 169: 115851. doi:10.1016/j.biopha.2023.115851. PMID 37976891. S2CID 265251138.
  7. Liszewski, Kathy (1 May 2023). "Multiple Vaccine Technologies Converge on Respiratory Syncytial Virus: Advances include a bivalent subunit vaccine, a liposome-based adjuvant, an mRNA vaccine, and a passive vaccination approach". Genetic Engineering & Biotechnology News. 43 (5): 16–18, 20. doi:10.1089/gen.43.05.05. S2CID 258583326.
  8. Messina, Alessandro; Germano, Chiara; Avellis, Vincenzo; Tavella, Elena; Dodaro, Valentina; Massaro, Alessio; Vitale, Raffaele; Masturzo, Bianca; Manzoni, Paolo (November 2022). "New strategies for the prevention of respiratory syncytial virus (RSV)". Early Human Development. 174: 105666. doi:10.1016/j.earlhumdev.2022.105666. PMID 36174288.


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: